NeurAxon To Focus On Migraine With Aura For Potential First-In-Class nNOS Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
A Phase II trial of NXN-188 missed the primary endpoint in migraine, but a post hoc analysis showed stronger efficacy in patients with history of aura.
You may also be interested in...
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Treximet will hit the U.S. market in mid-May, GSK says.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.